Voya Investment Management LLC Sells 43,758 Shares of ADMA Biologics Inc $ADMA

Key Points

• Voya Investment Management LLC has reduced its holdings in ADMA Biologics Inc by 4.8% in Q1, now owning 874,603 shares valued at approximately $17.35 million after selling 43,758 shares.
• During the same period, other large investors like Invesco Ltd. and Driehaus Capital Management LLC increased their stakes significantly, indicating strong institutional interest in ADMA Biologics.
• ADMA Biologics reported earnings of $0.15 per share, beating estimates, with revenues reaching $121.98 million, representing a 13.8% increase year-over-year.

Voya Investment Management LLC reduced its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 4.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 874,603 shares of the biotechnology company's stock after selling 43,758 shares during the quarter. Voya Investment Management LLC owned 0.37% of ADMA Biologics worth $17,352,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Cetera Investment Advisers grew its holdings in shares of ADMA Biologics by 1.3% during the first quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock worth $1,002,000 after purchasing an additional 670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ADMA Biologics by 1.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock worth $1,323,000 after purchasing an additional 711 shares during the last quarter. GF Fund Management CO. LTD. grew its holdings in shares of ADMA Biologics by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 1,089 shares during the last quarter. Journey Strategic Wealth LLC grew its holdings in shares of ADMA Biologics by 6.6% during the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock worth $354,000 after purchasing an additional 1,102 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of ADMA Biologics by 11.5% during the first quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock worth $223,000 after purchasing an additional 1,154 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.25 during trading hours on Friday, hitting $15.91. 8,438,957 shares of the company's stock were exchanged, compared to its average volume of 3,009,029. The stock's 50-day moving average is $17.22 and its 200-day moving average is $18.93. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 18.50 and a beta of 0.54. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business's revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.13 earnings per share. As a group, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.